Search

Your search keyword '"Saenger, Yvonne"' showing total 430 results

Search Constraints

Start Over You searched for: Author "Saenger, Yvonne" Remove constraint Author: "Saenger, Yvonne"
430 results on '"Saenger, Yvonne"'

Search Results

101. Radiomics machine-learning signature for diagnosis of hepatocellular carcinoma in cirrhotic patients with indeterminate liver nodules

102. Abstract 4068: Radiation, immune checkpoint inhibition, and modulation of the tumor immune microenvironment promotes immunologic rejection of established HPV-associated tumors

103. Abstract 2798: High density of CD68+HLA-DR-macrophages in the stroma of primary melanoma correlates with an unfavorable immune microenvironment as assessed by Digital Spatial Profiling

104. Nivolumab for hepatocellular carcinoma (HCC) in a real-world context.

105. Prediction of distant melanoma recurrence from primary tumor digital H&E images using deep learning.

106. Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II–III Melanoma

107. LBP-23-Prognostic Impact of Peritumoral Neutrophil Infiltration on Hepatocellular Carcinoma Recurrence Following Liver Transplantation

110. Tissue-Resident Memory T Cells Mediate Immune Homeostasis in the Human Pancreas Through the PD-1/PD-L1 Pathway

111. Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial

112. Abstract B31: Multiparameter profiling of abscopal effect (AbE) in a pediatric fibrosarcoma with EML4-NTRK3 fusion

113. Abstract B51: Quantitative multiplex immunofluorescence reveals that chemoradiation therapy favorably modulates the tumor immune microenvironment of pancreatic cancer

115. Abstract 2091: Quantitative compositional and spatial analysis of tumor microenvironment (TME) in primary melanoma

116. LGG-35. IDENTIFICATION OF SETD2 MUTATION IN AN AGGRESSIVE PILOCYTIC ASTROCYTOMA PRESENTING AS AN INFLAMMATORY OPTIC NERVE LESION

117. Quantitative multiplex immunofluorescence to identify candidate biomarkers of response to anti-PD1 in metastatic melanoma.

118. Validation of a prognostic 53-immune-gene panel in stage II/III melanoma.

119. Correlation of immune infiltration of cytotoxic T cells and activated microglia in glioblastoma (GBM) post anti-PD1 therapy with response.

123. Quantitative multiplex immune fluorescence to reveal the impact of chemoradiation therapy on modulation of the immune micro-environment of pancreatic ductal adenocarcinoma.

124. Association of Akt inhibition with change in immunophenotype of tumor microenvironment (TME) in breast cancer (BC).

125. Interrogating the sarcoma immune microenvironment (iME) using multiplex immunohistochemistry (mIHC).

126. Characterization and spatial localization of the tumor immune microenvironment in metastatic uveal melanoma.

127. Quantitative Analysis of Immune Infiltrates in Primary Melanoma

128. Introducing cancer convergence.

129. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

130. Introducing cancer convergence

131. Quality Assessment of Stereotactic Radiosurgery of a Melanoma Brain Metastases Model Using a Mouselike Phantom and the Small Animal Radiation Research Platform

132. 2367

133. Abstract 1671: Characterization of the immune landscape in stage II-III melanoma using qIF

134. Characterization of the tumor immune microenvironment (TIM) with multiplex immunohistochemistry (mIHC) in patients with breast cancer following treatment with MK-2206.

136. Trials in progress: A phase II study of in situ therapeutic vaccination against refractory solid cancers with intratumoral poly-ICLC.

139. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

140. Distinguishing melanophages from tumor in melanoma patients treated with talimogene laherparepvec

142. Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics.

144. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

145. In situ, therapeutic vaccination against refractory solid cancers with intratumoral Poly-ICLC: A phase I study.

147. Oncolytic virus therapy for cancer

148. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma

149. ATCT-33RESULTS FROM EARLY CLINICAL TRIALS FOR 4-DEMETHYL-4-CHOLESTERYLOXYCARBONYLPENCLOMEDINE (DM-CHOC-PEN)

150. Window of opportunity trial of HPV E7 antigen-expressing Listeria-based therapeutic vaccination prior to robotic surgery for HPV-positive oropharyngeal cancer.

Catalog

Books, media, physical & digital resources